Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event
17 Maggio 2024 - 2:30PM
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the
"Company"), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced the
successful exhibition of its Intelligent Fingerprinting Drug
Screening Solution at The Health & Safety Event 2024, the
United Kingdom’s largest annual technology showcase exhibiting
products and services that strengthen and support workplace safety
standards. According to the event website, this year's event
welcomed over 250+ industry-leading exhibitors and over 11,500
attendees, including visitors from major brands such as Amazon,
PepsiCo, Rolls Royce, Jaguar Land Rover, and Harvey
Nichols.
The Health & Safety Event has become a
crucial meeting place for individuals dedicated to maintaining safe
and efficient workplaces. It served as a prominent stage for INBS
to demonstrate its innovative drug screening technology. According
to the event website, 77% of those who attend the show are key
decision-makers, with 88% considering the show essential to their
business operations.
During the event Company representatives
facilitated live demonstrations with the participation of notable
clients such as Stewart Osmond, Haulage & Logistics Director at
WTW (Willis Towers Watson). Mr. Osmond discussed the company's
collaborative efforts in combating the under-addressed risk of drug
driving within the logistics sector, highlighting how the
Intelligent Fingerprinting solution has been pivotal in enhancing
fleet safety and compliance.
Additionally, the Company engaged in discussions
with its South American distributor about its initial steps towards
a pilot program aimed at integrating the Intelligent Fingerprinting
technology into hospitals and emergency services in Chile. This
prospective expansion reflects the global relevance and versatility
of the fingerprint-based drug screening solution.
Doug Heath, Vice President of Global Sales at
Intelligent Bio Solutions, commented, “This year's Health &
Safety Event marks our most successful yet. The surge in interest
and engagement from industry leaders and decision-makers validate
the effectiveness and necessity of our drug screening solution and
reflects the growing commitment across sectors to ensure a safer
workplace environment. Our presence at the event has significantly
broadened our reach and deepened our impact, facilitating key
discussions and opportunities that will drive the future of
workplace safety innovations.”
Harry Simeonidis, President & CEO at
Intelligent Bio Solutions, added, “Our success at the 2024 Health
& Safety Event reaffirms that our fingerprint drug screening
technology is well suited to meet the evolving safety needs of
industries worldwide. The high level of engaged and enthusiastic
feedback we received further fuels our dedication to advancing
non-invasive, rapid drug testing solutions. This event has been
pivotal in raising the profile of our business and showcasing our
drug screening technology. This year has set a new benchmark for
our continued success.”
The Intelligent Fingerprinting Drug Screening
System remains the world’s first to utilize fingerprint sweat for
rapid detection of recent drug use, including substances such as
cannabis, cocaine, opiates, and methamphetamine, delivering results
in under ten minutes.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is
a medical technology company delivering innovative, rapid,
non-invasive testing solutions. The Company believes that its
Intelligent Fingerprinting Drug Screening System will revolutionize
portable testing through fingerprint sweat analysis, which has the
potential for broader applications in additional fields. Designed
as a hygienic and cost-effective system, the test screens for
recent use of drugs commonly found in the workplace, including
opiates, cocaine, methamphetamine, and cannabis. With sample
collection in seconds and results in under ten minutes, this
technology would be a valuable tool for employers in
safety-critical industries. Additionally, the Company's biosensor
platform has the potential to test for various indications, ranging
from immunological conditions to communicable diseases. The
Company's current customer segments include construction,
manufacturing and engineering, transport and logistics firms, drug
treatment organizations, and coroners.
For more information,
visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.'s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals,
among others. Although Intelligent Bio Solutions Inc. believes that
the expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions Inc. has
attempted to identify forward-looking statements by terminology,
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions' public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Intelligent Bio Solutions
Inc.info@ibs.incLinkedIn | Twitter
Investor & Media Contact: Valter
Pinto, Managing Director KCSA Strategic
Communications PH: (212) 896-1254 INBS@kcsa.com
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Giu 2023 a Giu 2024